ViewRay Announces Conference Call for Third Quarter 2021 Financial Results to be Held After Market on November 4, 2021

Rhea-AI Summary

ViewRay, Inc. (Nasdaq: VRAY) announced it will release its third quarter 2021 financial results on November 4, 2021, followed by a conference call at 4:30 p.m. ET. The call will discuss anticipated future orders and financial performance related to its MRIdian® MR-Guided Radiation Therapy System. A live webcast will be available on the investor relations page, with a replay accessible for 14 days post-call. ViewRay highlighted the importance of addressing challenges in advanced radiation oncology through its innovative technology amidst potential market uncertainties and risks.

Positive

• Upcoming conference call scheduled for November 4, 2021, to discuss Q3 financial results.
• Focus on anticipated future orders and operating performance indicates potential growth.

Negative

• Forward-looking statements indicate risks due to competition, market conditions, and uncertainties from clinical trials.
• Ongoing effects of the COVID-19 pandemic may impact demand and operations.

CLEVELAND, Oct. 14, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2021 financial results.

ViewRay will hold a conference call to discuss results on Thursday, November 4, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The confirmation number is 5970168. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until November 11, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 5970168.

About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, anticipated future orders, and ViewRay's anticipated future operating and financial performance, treatment results and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the recent COVID-19 (coronavirus) pandemic, including its impacts across our businesses on demand, operations and our global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-third-quarter-2021-financial-results-to-be-held-after-market-on-november-4-2021-301399916.html

SOURCE ViewRay, Inc.

FAQ

When will ViewRay release its third quarter 2021 financial results?

ViewRay will release its third quarter 2021 financial results on November 4, 2021.

What time is the conference call for ViewRay's Q3 financial results?

The conference call is scheduled for 4:30 p.m. ET on November 4, 2021.

How can I access the conference call for ViewRay's financial results?

The conference call can be accessed via dial-in numbers provided in the press release, and a live webcast will be available on ViewRay's investor relations page.

What are some risks mentioned in ViewRay's press release?

Risks include competition, market conditions, and uncertainties from clinical trials, as well as the impacts of the COVID-19 pandemic.

What technology is ViewRay focused on in its operations?

ViewRay focuses on its MRIdian® MR-Guided Radiation Therapy System to address unique challenges in advanced radiation oncology.